Significant Ownership of ADAR1 Capital Management, LLC

Large-stake snapshot 1 signal
Large-stake filing summary
  • Recent SEC Schedule 13D/G filings for ADAR1 Capital Management, LLC focus on large-stake beneficial ownership disclosures and amendments.
  • Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
Manager Names, identifiers, and filing context for this profile. 2 identity fields
Manager signature
/s/ Daniel Schneeberger - Daniel Schneeberger, Manager
Manager location
Austin, TX

Follow Filing Activity

Follow ADAR1 Capital Management, LLC with Pro and return when a new Schedule 13D/G filing changes the record on this page.

Pro alert delivery is coming soon and remains tied to source-backed filing changes rather than inferred market advice.

Review Pro alert access Already have an account? Sign in and return here

Significant Ownership of ADAR1 Capital Management, LLC

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
INM InMed Pharmaceuticals, Inc. Common Shares, no par value 24% $512,000 800,000 ADAR1 Capital Management, LLC 31 May 2026
RLYB Rallybio Corporation Common Stock, par value $0.0001 per share 18% $13,293,151 926,352 ADAR1 Capital Management, LLC 31 May 2026
NXTC NextCure, Inc. Common Stock, $0.001 par value per share 16% $1,574,873 722,419 ADAR1 Capital Management, LLC 31 Jul 2026
IKT Inhibikase Therapeutics, Inc. Common Stock, $0.001 par value 9.9% $25,086,651 +$2,113,430 13,860,028 +9.2% ADAR1 Capital Management, LLC 31 Mar 2026
EQ Equillium, Inc. Common Stock, par value $0.0001 per share 9.9% $13,735,808 +$850,454 6,603,754 +6.6% ADAR1 Capital Management, LLC 31 Mar 2026
GRCE Grace Therapeutics, Inc. Common Stock, par value $0.0001 per share 9.9% $4,100,110 +$201,553 1,806,216 +5.2% ADAR1 Capital Management, LLC 30 Jun 2026
KPRX Kiora Pharmaceuticals, Inc. Common Stock, par value $0.01 per share 9.9% $1,250,197 +$289,812 475,378 +30% ADAR1 Capital Management GP, LLC 30 Jun 2026
ACST Grace Therapeutics, Inc. Common Stock, par value $0.0001 per share 9.9% 1,534,254 +2.1% ADAR1 Capital Management GP, LLC 30 Sep 2025
AMAN Amanat Acquisition Corp. Class A Ordinary Shares, par value $0.0001 per share 9.6% $7,597,500 750,000 ADAR1 Capital Management, LLC 30 Jun 2026
PLRX Pliant Therapeutics, Inc. Common Stock, par value $0.0001 per share 8.9% $6,281,085 5,509,724 ADAR1 Capital Management, LLC 30 Jun 2026
BOLD Boundless Bio, Inc. Common Stock, par value $0.0001 per share 8.8% $4,920,540 1,968,216 ADAR1 Capital Management, LLC 30 Jun 2026
Yarrow Bioscience, Inc. Common Stock, par value $0.0001 per share 8.8% 59,000 ADAR1 Capital Management, LLC 30 Jun 2026
RACC Research Alliance Corporation III Class A Ordinary Shares, par value $0.0001 per share 8.4% $7,345,000 650,000 ADAR1 Capital Management, LLC 30 Jun 2026
Freenome, Inc. Class A Ordinary Shares, par value $0.0001 per share 8.3% 674,695 ADAR1 Capital Management, LLC 30 Jun 2026
LONA LeonaBio, Inc. Common Stock, $0.0001 par value per share 7.7% $6,969,268 727,481 ADAR1 Capital Management, LLC 31 Mar 2026
CYCN Cyclerion Therapeutics, Inc. Common Stock, no par value 7% $1,174,115 298,757 ADAR1 Capital Management, LLC 30 Jun 2026
EDIT Editas Medicine, Inc. Common Stock, par value $0.0001 per share 5.8% $28,089,240 8,889,000 ADAR1 Capital Management, LLC 30 Jun 2026
HLXC Helix Acquisition Corp. III Class A ordinary shares, par value $0.0001 per share 5.6% $10,160,000 1,000,000 ADAR1 Capital Management, LLC 31 Mar 2026
OKUR OnKure Therapeutics, Inc. Class A Common Stock, par value $0.0001 per share 5.5% $10,208,399 -$894,932 2,238,684 -8.1% ADAR1 Capital Management, LLC 30 Jun 2026
JATT JATT II Acquisition Corp. Ordinary Shares, par value $0.0001 per share 5.4% $5,012,688 417,724 ADAR1 Capital Management, LLC 30 Jun 2026
ADGM Adagio Medical Holdings, Inc. Common Stock, par value $0.0001 per share 5.4% $785,710 1,205,447 0% ADAR1 Capital Management, LLC 30 Jun 2026
RNTX Rein Therapeutics, Inc. Common Stock, $0.001 par value per share 5.3% $4,455,000 4,500,000 ADAR1 Capital Management, LLC 30 Jun 2026
OVID Ovid Therapeutics Inc. Common Stock, par value $0.001 per share 5.1% $26,098,743 +$752,969 9,559,979 +3% ADAR1 Capital Management, LLC 30 Jun 2026
PCSC Perceptive Capital Solutions Corp Class A Ordinary Shares, par value $0.0001 per share 5.1% $6,202,258 456,720 ADAR1 Capital Management, LLC 31 Dec 2025
KALA KALA BIO, Inc. Common Stock, par value $0.001 per share 4.9% $1,270,559 298,955 ADAR1 Capital Management, LLC 31 Dec 2024
QNRX Quoin Pharmaceuticals, Ltd. American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share 4.9% $609,067 +$264,346 102,883 +77% ADAR1 Capital Management GP, LLC 31 Mar 2026
IBIO iBio, Inc. Common Stock, par value $0.001 per share 4.4% $3,433,244 -$1,123,655 1,351,671 -25% ADAR1 Capital Management, LLC 31 Dec 2025
ZURA ZURA BIO LIMITED Class A Ordinary Shares, par value $0.0001 per share 3.2% $2,991,241 2,077,251 ADAR1 Capital Management, LLC 31 Dec 2024
PRTA Prothena Corporation Public Limited Company Ordinary Shares, par value $0.01 per share 2.7% $14,338,396 -$18,601,691 1,469,098 -56% ADAR1 Capital Management, LLC 30 Sep 2025
SPRB Spruce Biosciences, Inc. Common Stock, par value $0.0001 per share 2.5% $3,276,148 +$470,108 67,717 +17% ADAR1 Capital Management, LLC 30 Jun 2026
BIOA BioAge Labs, Inc. Common Stock, par value $0.00001 per share 0.4% $2,419,746 -$32,157,900 135,560 -93% ADAR1 Capital Management, LLC 31 Dec 2025
CLRB Cellectar Biosciences, Inc. Common Stock, $0.00001 par value per share 0.1% 2,962 ADAR1 Capital Management, LLC 30 Jun 2025
KROS Keros Therapeutics, Inc. Common Stock, $0.0001 par value per share 0% $0 -$85,258,156 0 -100% ADAR1 Capital Management, LLC 15 Oct 2025

Schedules 13D/G Reported by ADAR1 Capital Management, LLC:

Sym Target Class Ownership Change Current shares Change Value Reporting name Form Report period Filing date
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .